Neovance

Overview

Neovance is the current standalone brand for the former Fortrea Patient Access / Fortrea Patient Access Services business, with deeper lineage back to Covance / Labcorp patient-access operations. Buyers searching Fortrea Patient Access or Covance Market Access should treat Neovance as the current operating vendor for this hub-services and non-commercial specialty-pharmacy capability set.

Neovance is a full-stack patient access services provider for specialty and complex therapies. It combines hub services, non-commercial specialty pharmacy, field reimbursement, and nursing support, giving manufacturers a single operating partner for access work that otherwise spans intake, coverage discovery, affordability, bridge or free-goods dispensing, patient education, and ongoing adherence support.

For a pharma launch team, Neovance is most relevant when the program needs both hub casework and manufacturer-supported dispensing operations rather than a software-only access workflow or a commercial specialty pharmacy network. The diligence question is how much of the program Neovance can own directly versus where it still coordinates with outside specialty pharmacies, data partners, field teams, and manufacturer systems.

Hub Capability Model

The framework below standardizes how Rx Almanac evaluates hub-services capabilities, so buyers can compare vendors like-for-like while the readout column stays vendor-specific. For this table, Neovance is evaluated as a full-stack patient access services provider with non-commercial specialty pharmacy, field reimbursement, and nursing support.

Capability	Buyer should compare	Neovance readout
Therapy initiation and enrollment intake	Digital and human intake, eConsent, missing-information resolution, provider/patient portals, and clean case creation.	Core intake workflow. Neovance fits programs where intake, missing-information work, enrollment, and case creation need to be configured around the drug and indication.
Benefits verification and coverage triage	Medical/pharmacy benefit verification, eligibility checks, payer-policy lookup, coverage routing, and speed from referral to actionable case.	Core coverage workflow. Benefit verification is a central hub function, with company materials also point to voice-AI support for payer-call automation.
Prior authorization, appeals, and reimbursement casework	PA initiation, payer-specific forms, clinical documentation, appeals, denial management, and field reimbursement handoffs.	Core PA casework. Neovance should be evaluated on PA execution, appeals support, local policy navigation, and handoffs to field reimbursement resources.
Affordability, PAP, and copay operations	Copay, free-drug, bridge, foundation, income verification, PAP renewal, and gross-to-net sensitive affordability logic.	Core affordability operations. The non-commercial pharmacy and hub stack make Neovance especially relevant for PAP, bridge, quick-start, replacement, and free-goods workflows.
Patient engagement and adherence operations	Omnichannel reminders, clinical education, nursing or training escalation, persistence outreach, and patient-facing support quality.	Core engagement model. Nursing and patient-support operations are part of the profile; buyers should inspect escalation protocols, clinical boundaries, and adherence metrics.
Fulfillment, specialty pharmacy, and distribution coordination	Routing to SPs, non-commercial dispensing, DTP shipment, sample/replacement product, 3PL, and cold-chain handoffs.	Differentiated for non-commercial dispensing. Neovance’s owned non-commercial specialty pharmacy is a meaningful differentiator for free-drug, bridge, quick-start, and replacement programs, but buyers should not treat it as a covered-drug commercial SP network.
Program reporting, integrations, and governance	Manufacturer dashboards, KPI reporting, CRM/EHR/API integrations, SLA governance, and operating visibility across vendors.	Critical diligence item. The proprietary engagement platform and analytics posture are important, but buyers should validate data feeds, reporting cadence, QA sampling, audit trails, and manufacturer system integrations by brand.

Buyer Fit

• Strongest fit: Specialty launches that need hub operations plus manufacturer-supported dispensing, field reimbursement, and patient education under one operating model.
• Stronger fit: Rare disease, biologics, diabetes, neurology, immunology, oncology, ophthalmology, and other high-friction access programs where payer rules, free-drug logic, cold-chain handling, and patient training matter.
• Less natural fit: Programs that only need a lightweight BV/PA software layer, broad commercial specialty-pharmacy network access, or a global commercialization partner covering field sales, media, 3PL, and distribution.
• Operating model: Clarify whether Neovance is the prime hub vendor, the non-commercial pharmacy operator, the nursing/FRM provider, or one component inside a larger launch-services stack.
• Governance diligence: Confirm launch-surge staffing, turnaround-time baselines, pharmacy-state licensing, cold-chain capacity, patient communications, data feeds, adverse-event routing, and reporting granularity.

Differentiators

• Owned non-commercial specialty pharmacy: Useful for manufacturers that want tighter control over free-drug, bridge, quick-start, replacement, and PAP dispensing workflows.
• Four-pillar service model: Hub, non-commercial SP, field reimbursement, and nursing support can be scoped together rather than assembled from separate point vendors.
• Indication-level program design: Neovance emphasizes configuring access operations around drug-specific payer friction rather than applying a generic hub template.
• Voice-AI assisted payer work: Public partner materials point to Infinitus voice AI for benefit-verification and payer-call automation, making automation diligence central to the RFP.
• Scale and heritage: The profile points to large-pharma experience, broad disease-area coverage, and a Fortrea/Covance lineage that may matter for complex launch operations.

RFP Questions

• Which workflows are handled by Neovance directly versus by manufacturer systems, commercial specialty pharmacies, 3PLs, affordability vendors, or field partners?
• What median time-to-therapy, BV turnaround, PA turnaround, approval rate, first-fill conversion, bridge conversion, and abandonment metrics can be reported by brand and payer?
• Which PAP, free-goods, bridge, quick-start, replacement, and cold-chain dispensing workflows are supported by the owned non-commercial pharmacy?
• How are payer-call automation, manual casework, pharmacist review, field reimbursement, and nursing escalation separated in SOPs and QA?
• What pharmacy licenses, REMS procedures, DEA/state-board controls, HIPAA controls, adverse-event routing, and product-complaint workflows apply to the proposed program?
• Which manufacturer dashboards, CRM feeds, hub portals, EHR touchpoints, data warehouses, and audit logs are production-ready?
• What happens during launch surge, payer-policy changes, supply constraints, cold-chain excursions, or patient-assistance eligibility changes?

Recent Activity

• 2026: Buyer diligence should treat CareMetx’s expansion into Cencora’s U.S. hub and free-goods pharmacy operations as a competitive-context shift for Neovance, especially in free-goods pharmacy and scaled patient access.
• 2025: Public partner material highlighted Infinitus voice AI support for benefit-verification workflows, including reported time savings per case.
• 2025: Neovance messaging emphasized a proprietary Customer Engagement Platform, predictive analytics, and the “human plus technology” operating model for patient access.
• 2024: The Neovance brand emerged from Fortrea Patient Access, giving the current company a new standalone identity while retaining the legacy patient-access services lineage.